NASDAQ:CAPS Capstone Therapeutics Q1 2026 Earnings Report $0.18 0.00 (-0.38%) As of 11:29 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Capstone Therapeutics EPS ResultsActual EPS-$0.21Consensus EPS -$0.19Beat/MissMissed by -$0.02One Year Ago EPSN/ACapstone Therapeutics Revenue ResultsActual Revenue$12.64 millionExpected Revenue$10.80 millionBeat/MissBeat by +$1.84 millionYoY Revenue GrowthN/ACapstone Therapeutics Announcement DetailsQuarterQ1 2026Date5/20/2026TimeBefore Market OpensConference Call DateWednesday, May 20, 2026Conference Call Time7:00AM ETUpcoming EarningsCapstone Therapeutics' Q3 2026 earnings is estimated for Friday, November 6, 2026, based on past reporting schedulesConference Call ResourcesSlide DeckPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfileSlide DeckFull Screen Slide DeckPowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Capstone Therapeutics Earnings HeadlinesCapstone Publishes Investor FAQ: 75% of Convertible Note Principal Retired, Approximately $1.72 Million RemainingAugust 26, 2026 | businesswire.comCapstone Reports Q2 2026 Results: Revenue Up 67%, Gross Profit Up 92%, Stone Business Adjusted EBITDA Turns Positive as GuidedAugust 12, 2026 | businesswire.comThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.September 11 at 1:00 AM | Investors Alley (Ad)Capstone Receives Additional 180-Day Nasdaq Compliance PeriodJuly 9, 2026 | businesswire.comCapstone Extends Credit Facilities with Beacon Bank and Stream Finance on Identical TermsJune 22, 2026 | businesswire.comCapstone Expands D.R. Horton Relationship to 19 Communities and Wins All of a Leading National Homebuilder's Regional Stone WorkJune 1, 2026 | businesswire.comSee More Capstone Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Capstone Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Capstone Therapeutics and other key companies, straight to your email. Email Address About Capstone TherapeuticsCapstone Therapeutics (NASDAQ:CAPS), a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.View Capstone Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles AeroVironment's Record Backlog and Earnings Beat Fuel Recovery CaseCould Snowflake's Big Quarter Be a Sign of More to Come?Microsoft’s Azure Reporting Shift Adds Clarity, But the Bull Case Came FirstGameStop’s Comeback Case Is Getting Interesting, But eBay Still Looks StrongerChewy’s Sell-Off Puts Its Recurring Revenue Story Back on Trial for InvestorsWhy Braze’s Guidance Miss May Be a Gift for InvestorsCasey’s Post-Earnings Drop May Give Investors a Better Entry Into a Quality Retailer Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.